Dr Junxian Lim
Research Officer
Institute for Molecular Bioscience
+61 7 334 62386
Journal Articles
Tng, Jiahui, Lim, Junxian, Wu, Kai-Chen, Lucke, Andrew J., Xu, Weijun, Reid, Robert C. and Fairlie, David P. (2020). Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation. Journal of Medicinal Chemistry, 63 (11) acs.jmedchem.0c00230, 5956-5971. doi:10.1021/acs.jmedchem.0c00230
Rowley, Jessica A., Reid, Robert C., Poon, Eunice K. Y., Wu, Kai-Chen, Lim, Junxian, Lohman, Rink-Jan, Hamidon, Johan K., Yau, Mei-Kwan, Halili, Maria A., Durek, Thomas, Iyer, Abishek and Fairlie, David P. (2020). Potent thiophene antagonists of human complement C3a receptor with anti-inflammatory activity. Journal of Medicinal Chemistry, 63 (2) acs.jmedchem.9b00927, 529-541. doi:10.1021/acs.jmedchem.9b00927
de Araujo, Aline D., Lim, Junxian, Wu, Kai-Chen, Xiang, Yibin, Good, Andrew C., Skerlj, Renato and Fairlie, David P. (2018) Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins. Journal of Medicinal Chemistry, 61 7: 2962-2972. doi:10.1021/acs.jmedchem.8b00010
Jiang, Yuhong, Yau, Mei-Kwan, Lim, Junxian, Wu, Kai-Chen, Xu, Weijun, Suen, Jacky Y and Fairlie, David P (2018). A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. The Journal of pharmacology and experimental therapeutics, 364 (2) 246-257. doi:10.1124/jpet.117.245027
Lohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, doi:10.1038/s41467-017-00414-w
Dantas de Araujo, Aline, Wu, Chongyang, Wu, Kai-Chen, Reid, Robert C., Durek, Thomas, Lim, Junxian and Fairlie, David P. (2017). Europium-labeled synthetic C3a protein as a novel fluorescent probe for human complement C3a receptor. Bioconjugate Chemistry, 28 (6) 1669-1676. doi:10.1021/acs.bioconjchem.7b00132
Jiang, Yuhong, Yau, Mei-Kwan, Kok, W. Mei, Lim, Junxian, Wu, Kai-Chen, Liu, Ligong, Hill, Timothy A., Suen, Jacky Y. and Fairlie, David P. (2017). Biased signaling by agonists of protease activated receptor 2. ACS Chemical Biology, 12 (5) 1217-1226. doi:10.1021/acschembio.6b01088
Suen, J.Y., Adams, M. N., Lim, J., Madala, P.K., Xu, W, Cotterell, A., He, Y., Yua, Mei-Kwan, Hooper, J. D. and Fairlie, D.P. (2017). Mapping transmembrane residues of proteinase activated recpetor 2 (PAR2) that influence ligand-modulated calcium signaling. Pharmacological Research, 117328-342. doi:10.1016/j.phrs.2016.12.020
Dantas De Araujo, Aline, Lim, Junxian, Good, Andrew C., Skerlj, Renato T. and Fairlie, David P. (2017). Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site. ACS Medicinal Chemistry Letters, 8 (1) 22-26. doi:10.1021/acsmedchemlett.6b00395
Seow, Vernon, Lim, Junxian, Cotterell, Adam J., Yau, Mei-Kwan, Xu, Weijun, Lohman, Rink-Jan, Kok, W. Mei, Stoermer, Martin J., Sweet, Matthew J., Reid, Robert C., Suen, Jacky Y. and Farilie, David P. (2016). Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Scientific Reports, 6 (1) 24575, 24575.1-24575.12. doi:10.1038/srep24575
Yau, Mei-Kwan, Lim, Junxian, Liu, Ligong and Fairlie, David P. (2016). Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015). Expert Opinion on Therapeutic Patents, 26 (4) 471-483. doi:10.1517/13543776.2016.1154540
Yau, Mei-Kwan, Liu, Ligong, Lim, Junxian, Lohman, Rink-Jan, Cotterell, Adam J., Suen, Jacky Y., Vesey, David A., Reid, Robert C. and Fairlie, David P. (2016). Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. Bioorganic and Medicinal Chemistry Letters, 26 (3) 986-991. doi:10.1016/j.bmcl.2015.12.048
Yau, Mei-Kwan, Liu, Ligong, Suen, Jacky Y., Lim, Junxian, Lohman, Rink-Jan, Jiang, Yuhong, Cotterell, Adam J., Barry, Grant D., Mak, Jeffrey Y. W., Vesey, David A., Reid, Robert C. and Fairlie, David P. (2016). PAR2 modulators derived from GB88. ACS Medicinal Chemistry Letters, 7 (12) 1179-1184. doi:10.1021/acsmedchemlett.6b00306
Yau, Mei-Kwan, Suen, Jacky Y., Xu, Weijun, Lim, Junxian, Liu, Ligong, Adams, Mark N., He, Yaowu, Hooper, John D., Reid, Robert C. and Fairlie, David P. (2016). Potent small agonists of protease activated receptor 2. ACS Medicinal Chemistry Letters, 7 (1) 105-110. doi:10.1021/acsmedchemlett.5b00429
Xu, Weijun, Lim, Junxian, Goh, Chai-Yeen, Suen, Jacky Y., Jiang, Yuhong, Yau, Mei-Kwan, Wu, Kai-Chen, Liu, Ligong and Fairlie, David P. (2015). Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. Journal of Chemical Information and Modeling, 55 (10) 2079-2084. doi:10.1021/acs.jcim.5b00500
Perry, Samuel R., Xu, Weijun, Wirija, Anna, Lim, Junxian, Yau, Mei-Kwan, Stoermer, Martin J., Lucke, Andrew J. and Fairlie, David P. (2015). Three homology models for PAR2 derived from different templates: Application to antagonist discovery. Journal of Chemical Information And Modeling, 55 (6) 1181-1191. doi:10.1021/acs.jcim.5b00087
Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Hamidon, Johan K., Lim, Junxian, Stoermer, Martin J. and Fairlie, David P. (2014). Potent heterocyclic ligands for human complement C3a receptor. Journal of Medicinal Chemistry, 57 (20) 8459-8470. doi:10.1021/jm500956p
Suen, J. Y., Cotterell, A., Lohman, R. J., Lim, J., Han, A., Yau, M. K., Liu, L., Cooper, M. A., Vesey, D. A. and Fairlie, D. P. (2014). Pathway-selective antagonism of proteinase activated receptor 2. British Journal of Pharmacology, 171 (17) 4112-4124. doi:10.1111/bph.12757
Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Lim, Junxian and Fairlie, David P. (2014). Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides. Journal of the American Chemical Society, 136 (34) 11914-11917. doi:10.1021/ja506518t
Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Hamidon, Johan K., Reed, Anthony N., Chu, Peifei, Suen, Jacky Y., Stoermer, Martin J., Blakeney, Jade S., Lim, Junxian, Faber, Jonathan M. and David P. Fairlie, (2013). Downsizing a human inflammatory protein to a small molecule with equal potency and functionality. Nature Communications, 4 (2802) 2802, 1-9. doi:10.1038/ncomms3802
Lim, Junxian, Iyer, Abishek, Liu, Ligong, Suen, Jacky Y., Lohman, Rink-Jan, Seow, Vernon, Yau, Mei-Kwan, Brown, Lindsay and Fairlie, David P. (2013). Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. The FASEB Journal, 27 (12) 4757-4767. doi:10.1096/fj.13-232702
Iyer, Abishek, Fenning, Andrew, Lim, Junxian, Le, Giang T, Reid, Robert C, Halili, Maria A, Fairlie, David P and Brown, Lindsay (2010). Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. British Journal of Pharmacology, 159 (7) 1408-1417. doi:10.1111/j.1476-5381.2010.00637.x
Ruiz-Gomez, G, Lim, J, Halili, M. A., Le, G. T., Madala, P. K., Abbenante, G and Fairlie, D. P. (2009). Structure-activity relationships for substrate-based inhibitors of human complement factor B. JOURNAL OF MEDICINAL CHEMISTRY, 52 (19) 6042-6052. doi:10.1021/jm900781m
Conference Paper
Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015).Downsizing Proteins Without Losing Potency or Function. American Peptide Symposium 2015, Orlando , Florida, United States, 20-25 June 2015. American Peptide Society. doi: 10.17952/24APS.2015.016